The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III, randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy.
Robert Dreicer
Consultant or Advisory Role - EMD Serono; Janssen; Lilly; Millennium; Sanofi
Honoraria - Janssen; Millennium
Research Funding - Millennium
David B. Agus
Consultant or Advisory Role - Millennium
Joaquim Bellmunt
Consultant or Advisory Role - Takeda
Johann Sebastian De Bono
Consultant or Advisory Role - Astellas Pharma; Johnson & Johnson; Medivation; Sanofi
Honoraria - Astellas Pharma; Johnson & Johnson; Medivation; Sanofi
Research Funding - AstraZeneca
Daniel Peter Petrylak
Consultant or Advisory Role - Centicor; Millennium
Bindu Tejura
Employment or Leadership Position - Millennium
Yuanjun Shi
Employment or Leadership Position - Millennium
Karim Fizazi
Consultant or Advisory Role - Millennium
Research Funding - Millennium